Related Experiment Videos
Intrathecal baclofen in X-linked adrenoleukodystrophy
M L Chu1, D A Sala, H L Weiner
1The Center for Children, Hospital for Joint Diseases and New York University Hospitals Center, New York, NY 10003, USA.
Pediatric Neurology
|March 29, 2001
Summary
Continuous intrathecal baclofen effectively managed severe spasticity in an 8-year-old with X-linked adrenoleukodystrophy. This treatment improved the patient's quality of life, reducing pain and easing care.
Area of Science:
- Neurodegenerative Disorders
- Pediatric Neurology
- Pharmacology
Background:
- X-linked adrenoleukodystrophy (X-ALD) is a progressive neurodegenerative disorder characterized by white matter destruction and adrenal insufficiency.
- Symptoms typically manifest between ages 4-8, including spasticity, visual impairment, dysphagia, and seizures, significantly impacting quality of life.
Observation:
- This report details the case of an 8-year-old patient with X-ALD experiencing severe spasticity.
- The patient received continuous infusion of intrathecal baclofen as a therapeutic intervention.
Findings:
- Intrathecal baclofen administration led to significant improvement in the patient's spasticity.
- Key outcomes included the elimination of pain and enhanced ease of care for the patient.
Implications:
- Intrathecal baclofen represents a viable treatment option for managing spasticity in X-ALD.
- This approach may also benefit pediatric and adult patients with spasticity due to other neurodegenerative conditions.